The bilateral infusions of AB-1005 were well tolerated, without any SAEs linked to the gene therapy or contrast agent.
AskBio Parkinson’s and MSA Scientific chair Krystof Bankiewicz said: “These early findings are encouraging and show AB-1005 to be well tolerated in this study in patients with mild to moderate Parkinson’s disease.
Vascular Dysfunction in the Brain as an Initiating Event in Parkinson’s Disease
Constipation in Parkinson’s disease
